What Is a High BMI? NHS Thresholds Explained

Understanding what a high BMI means is an important step in assessing your overall health and identifying any associated risks. BMI, or body mass index, is a widely used screening tool that helps healthcare professionals categorise weight status in adults and children. While it has well-recognised limitations, it remains a practical starting point for clinical conversations about weight management. This article explains how BMI is calculated, what the NHS considers a high BMI, the health conditions linked to excess weight, and the evidence-based options available if your BMI falls above the recommended range.

What is BMI and how is it calculated?

BMI is calculated by dividing weight in kilograms by the square of height in metres. It is a practical screening tool but cannot distinguish fat from muscle mass, so it should be used alongside waist circumference and other clinical measures.

BMI, or body mass index, is a numerical measure calculated by dividing a person's weight in kilograms by the square of their height in metres (kg/m²).^[1][4] It is widely used by healthcare professionals as a simple, population-level screening tool to categorise weight status and identify individuals who may be at increased health risk. For example, a person weighing 80 kg who is 1.75 m tall has a BMI of approximately 26.1.

BMI is straightforward to calculate and requires no specialist equipment, which makes it practical for use in clinical settings and public health surveys. However, it has recognised limitations: it does not directly measure body fat, and it cannot distinguish between fat mass and muscle mass. A highly muscular individual may have a high BMI without carrying excess body fat, while an older adult with low muscle mass may have a normal BMI despite an unhealthy proportion of body fat.

For these reasons, BMI is best interpreted alongside other clinical information. The NHS and NICE both acknowledge that BMI is a useful screening tool that informs risk and eligibility for certain interventions, but it is not diagnostic on its own. Complementary measures include waist circumference and waist-to-height ratio (a ratio below 0.5 is generally considered healthy), as well as blood pressure, blood glucose and cholesterol levels. Importantly, BMI thresholds are adjusted for people from Black, Asian and minority ethnic backgrounds, as evidence reviewed by NICE suggests that health risks associated with excess weight can occur at lower BMI values in these groups.^[3][5]

What counts as a high BMI according to NHS guidelines?

The NHS classifies a BMI of 25.0 or above as overweight and 30.0 or above as obese. Lower thresholds of 23.0 and 27.5 apply to South Asian, Chinese and Black African or African-Caribbean adults.

According to NHS guidelines, a BMI of 25.0 or above is considered above the healthy range, with a BMI of 30.0 or above classified as obese. The standard NHS BMI categories for adults are as follows:

• Below 18.5: Underweight

• 18.5 to 24.9: Healthy weight

• 25.0 to 29.9: Overweight

• 30.0 to 34.9: Obese (Class I)

• 35.0 to 39.9: Obese (Class II)

• 40.0 and above: Severely obese (Class III)

For adults from South Asian, Chinese, Black African or African-Caribbean backgrounds, NICE guidance recommends using lower thresholds. In these groups, a BMI of 23.0 or above may indicate increased risk, and a BMI of 27.5 or above is used as the threshold equivalent to 30.0 in white European populations.

For children and young people, BMI is assessed differently using age- and sex-specific centile charts, because healthy BMI ranges change as children grow. UK growth charts and the NHS child BMI tool (based on RCPCH reference data) are used for this purpose. A child is generally considered to have a high BMI if their measurement falls at or above the 91st centile for their age and sex, with the 98th centile used as the threshold for clinical obesity.^[7]

It is worth noting that BMI thresholds are used to guide clinical decision-making and eligibility for certain interventions, but they are not the sole determinant of health. A clinician will consider the full clinical picture before recommending any course of action.

What health risks are linked to a high BMI?

A high BMI is associated with type 2 diabetes, cardiovascular disease, at least 13 cancers, sleep apnoea, liver disease and osteoarthritis. Central abdominal fat further increases cardiometabolic risk beyond BMI alone.

A high BMI is associated with a significantly increased risk of several serious long-term health conditions, including type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal problems. The relationship between excess body weight and these conditions is well established in the medical literature and underpins public health efforts to support people in reaching and maintaining a healthy weight.

Carrying excess weight, particularly around the abdomen, is linked to insulin resistance, raised blood pressure, abnormal cholesterol levels and chronic low-grade inflammation, all of which contribute to cardiovascular risk. People with a BMI in the obese range have a substantially higher likelihood of developing type 2 diabetes compared with those in the healthy weight range. Excess weight is also associated with an increased risk of at least 13 types of cancer, including breast, bowel and endometrial cancers, according to Cancer Research UK. Central adiposity (for example, an elevated waist-to-height ratio) further increases cardiometabolic risk beyond BMI alone.

Beyond metabolic and cardiovascular effects, a high BMI can contribute to:

• Sleep apnoea, where breathing repeatedly stops during sleep

• Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD)^[16]

• Osteoarthritis, particularly affecting the knees and hips

• Gastro-oesophageal reflux disease

• Mental health difficulties, including depression and reduced quality of life

It is important to approach these associations with sensitivity. Not every person with a high BMI will develop these conditions, and other factors, including physical activity levels, diet, genetics and socioeconomic circumstances, all play a role. The aim of discussing health risks is to support informed decision-making, not to cause alarm or stigma.

What can you do if your BMI is higher than recommended?

Speaking to your GP is the recommended first step; they can assess your health and refer you to structured lifestyle programmes or specialist weight management services. Licensed medicines such as semaglutide or tirzepatide may be considered for eligible individuals.

If your BMI is higher than the recommended range, the most effective first step is to speak with your GP, who can assess your overall health, identify any underlying conditions, and discuss appropriate support options. Sustainable weight management typically involves a combination of dietary changes, increased physical activity and behavioural support, and the right approach will depend on your individual circumstances.

NICE guidance on weight management recommends a tiered approach. For many people, structured lifestyle programmes, including calorie-controlled eating plans and regular moderate-intensity physical activity, form the foundation of treatment. Your GP or a referral to a specialist weight management service can help you access these resources. NHS Tier 3 and Tier 4 services are available in some areas for people with more complex needs, though access varies by Integrated Care Board and depends on local commissioning arrangements.

For eligible individuals, NICE has appraised certain medicines to support weight management alongside lifestyle changes. The following are among the licensed options in the UK, though this list is not exhaustive and eligibility depends on BMI thresholds, the presence of weight-related health conditions, and clinical assessment:

• Orlistat (Xenical, Alli), which reduces fat absorption in the gut^[8]

• Semaglutide (Wegovy), a GLP-1 receptor agonist available in doses up to 2.4 mg weekly by injection, with a higher 7.2 mg strength also authorised by the MHRA; NICE has appraised semaglutide for weight management in adults^[10]

• Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist authorised in the UK for both type 2 diabetes and chronic weight management; NICE has appraised tirzepatide for weight management in adults^[11][12]

• Orforglipron (Foundayo), an oral GLP-1 receptor agonist that has received a UK marketing authorisation for weight management^[14]

Access to these medicines through the NHS depends on national commissioning decisions, local ICB pathways and individual clinical eligibility; not all options may be available in every area. These medicines are not appropriate during pregnancy or breastfeeding, and anyone planning a pregnancy should discuss this with their clinician before starting or continuing treatment.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a prescriber may consider appropriate options following a thorough clinical assessment.

In cases of severe obesity where other treatments have not been effective, bariatric surgery may be considered through NHS referral pathways, subject to NICE eligibility criteria.

Scientific References

1. Calculate your body mass index (BMI) for adults.
2. Calculate your waist to height ratio.
3. Overweight and obesity management (NG246) – Identifying and assessing overweight, obesity and central adiposity.
4. Overweight and obesity in adults.
5. BMI: preventing ill health and premature death in black, Asian and other minority ethnic groups (PH46).
6. NG246 Appendix A1: Summary of evidence from surveillance (PH46).
7. Calculate body mass index (BMI) for children and teenagers.
8. Orlistat: a medicine to treat obesity.
9. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity.
10. Semaglutide for managing overweight and obesity (TA875).
11. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
12. Tirzepatide: a medicine to manage type 2 diabetes and obesity.
13. Tirzepatide for managing overweight and obesity (TA1026).
14. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
15. Overweight and obesity management (NG246) – Medicines and surgery.
16. Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease. Clinical and Molecular Hepatology..

Frequently Asked Questions